Vascular Biogenics Ltd (VBLT)

[gr8db8]

LifeSci summary on KOL - pretty good read:
https://www.baystreet.ca/articles/research_reports/lifesci/NovelImmuno041117.pdf

If MOSPD2 is targeted as a treatment for cancer, depleted macrophage levels can be managed with Amgen’s (NasdaqGS: AMGN) Neuopogen (filgrastim), which is able to boost white blood cell counts. Because of this, MOSPD2 could be a viable cancer target since the damage caused to non-cancer cells, being macrophages, can be treated. The function of MOSPD2 was not previously well known, but through a series of studies investigating the mechanism of monocyte migration, VBL has so far identified that it has the following characteristics:

? Expressed on the cell surface of monocytes.
? Involved in cell migration and metastasis, making it an attractive target.
? Protein is expressed in many types of solid tumors.
? MOSPD2 correlates with tumor invasiveness in breast cancer